Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis

Diabetes Research and Clinical Practice

Volumn 110, Issue 1, 2015, Pages 26-37

  Sun, Feng ^a,b   Wu, Shanshan ^c   Guo, Shuxia ^b   Yu, Kai ^d   Yang, Zhirong ^a,e   Li, Lishi ^a,f   Zhang, Yuan ^a   Quan, Xiaochi ^a   Ji, Linong ^g   Zhan, Siyan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b SHIHEZI UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d TIANJIN FIFTH CENTRAL HOSPITAL   (China)

^e SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Blood pressure; GLP 1 receptor agonists; Heart rate; Hypertension; Network meta analysis; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; PLACEBO; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; SULFONYLUREA DERIVATIVE; VENOM;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RESPONSE; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; HEART RATE; HUMAN; HYPERTENSION; INCIDENCE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; AGONISTS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; META ANALYSIS; PATHOPHYSIOLOGY;

BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEART RATE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; LIRAGLUTIDE; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS; VENOMS;

EID: 84943197778     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.07.015     Document Type: Article

References (42)

1. Hansen K.B., Knop F.K., Holst J.J., Vilsbøll T. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int J Clin Pract 2009, 63:1154-1160.
2. Goykhman S., Drincic A., Desmangles J.C., Rendell M. Insulin Glargine: a review 8 years after its introduction. Expert Opin Pharmacother 2009, 10:705-718.
3. Nauck M.A., Heimesaat M.M., Behle K., Holst J.J., Nauck M.S., Ritzel R., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocr Metab 2002, 87:1239-1246.
4. Vilsbøll T., Krarup T., Madsbad S., Holst J.J. Both GLP-l and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Peptides 2003, 114:115-121.
5. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide-1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
6. Jurado J., Ybarra J., Solanas P., Caula J., Gich I., Pou J.M., et al. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. J Am Acad Nurse Pract 2009, 21:140-148.
7. Choe H.M., Townsend K.A., Blount G., Lo C.H., Sadowski L., Standiford C.J. Treatment and control of blood pressure in patients with diabetes mellitus. Am J Health Syst Pharm 2007, 64:97-103.
8. Jones S., Benroubi M., Castell C., Goday A., Liebl A., Timlin L., et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin 2009, 25:691-700.
9. Grundy S.M., Pasternak R., Greenland P., Smith S., Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999, 100:1481-1492.
10. Patel A., ADVANCE Collaborative Group, MacMahon S., Chalmers J., Neal B., Woodward M., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007, 370:829-840.
11. Kannel W.B., Kannel C., Paffenbarger R.S., Cupples L.A. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987, 113:1489-1494.
12. Carnethon M.R., Yan L., Greenland P., Garside D.B., Dyer A.R., Metzger B., et al. Resting heart rate in middle age and diabetes development in older age. Diabetes Care 2008, 31:335-339.
13. Stein P.K., Barzilay J.I., Domitrovich P.P., Chaves P.M., Gottdiener J.S., Heckbert S.R., et al. The relationship of heart rate and heart rate variability to non-diabetic fasting glucose levels and the metabolic syndrome: the Cardiovascular Health Study. Diabetic Med 2007, 24:855-863.
14. Wang B., Zhong J., Lin H., Zhao Z., Yan Z., He H., et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013, 15:737-749.
15. Robinson L.E., Holt T.A., Rees K., Randeva H.S., O'Hare J.P. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013, 3:e001986.
16. Monami M., Dicembrini I., Nardini C., Fiordelli I., Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014, 16:38-47.
17. Katout M., Zhu H., Rutsky J., Shah P., Brook R.D., Zhong J., et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens 2014, 27:130-139.
18. Van Valkenhoef G., Lu G., de Brock B., Hillege H., Ades A.E., Welton N.J. Automating network meta-analysis. Res Synth Methods 2012, 3:285-299.
19. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
20. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
21. Lu G., Ades A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23:3105-3124.
22. Salanti G., Ades A.E., Ioannidis J.P. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011, 64:163-171.
23. Spiegelhalter D.J., Best N.G., Carlin B.P., Van Der Linde A. Bayesian measures of model complexity an fit. J R Stat Soc 2002, 64:583-639.
24. Song F., Altman D.G., Glenny A.M., Deeks J.J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326:472.
25. Mundil D., Cameron-Vendrig A., Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diabetics Vasc Dis Res 2012, 9:95-108.
26. Lorber D. GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther 2013, 31:238-249.
27. Okerson T., Yan P., Stonehouse A., Brodow R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010, 23:334-339.
28. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
29. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259.
30. Varanasi A., Chaudhuri A., Dhindsa S., Arora A., Lohano T., Vora M.R., et al. Durability of effects of exenatide on glycaemic control, body weight, systolic blood pressure, C-reactive protein and triglyceride concentrations. Endocr Pract 2011, 17:192-200.
31. Gutzwiller J.P., Tschopp S., Bock A., Zehnder C.E., Huber A.R., Kreyenbuehl M., et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004, 89:3055-3061.
32. Basu A., Charkoudian N., Schrage W., Rizza R.A., Basu R., Joyner M.J. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007, 293:E1289-E1295.
33. Nyström T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahrén B., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215.
34. Erdogdu O., Nathanson D., Sjöholm A., Nyström T., Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 2010, 325:26-35.
35. Ding L., Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin 2012, 33:75-81.
36. Sivertsen J., Rosenmeier J., Holst J.J., Vilsbøll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012, 9:209-222.
37. Wang B., Ni Y., Zhong J., Sun F. Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension. J Diabetes 2012, 4:22-29.
38. Valensi P., Chiheb S., Fysekidis M. Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter. Diabetologia 2013, 56:1196-1200.
39. Wei Y., Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 1996, 157:355-357.
40. Wahren J. C-peptide: new findings and therapeutic implications in diabetes. Clin Physiol Funct Imaging 2004, 24:180-189.
41. The MACB Study Group Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. Eur Heart J 1995, 16:1825-1832.
42. Caldwell D.M., Ades A.E., Higgins J.P. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331:897-900.